Nonetheless, given that our strategy identified several well-known AML susceptibility genes, such as RUNX1, FLT3, and SPI1 (PU.1) [6,47,48], the validity of our approach is demonstrated. This evidence concerns the gene SPI1 and acute myeloid leukemia.